- Home
- TOPS vs MURA Comparison
TOPS vs MURA Comparison
Compare TOPS & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- MURA
- Stock Information
- Founded
- TOPS 2000
- MURA 2013
- Country
- TOPS Greece
- MURA Ireland
- Employees
- TOPS N/A
- MURA N/A
- Industry
- TOPS Marine Transportation
- MURA
- Sector
- TOPS Consumer Discretionary
- MURA
- Exchange
- TOPS Nasdaq
- MURA Nasdaq
- Market Cap
- TOPS 27.2M
- MURA 30.7M
- IPO Year
- TOPS 2004
- MURA N/A
- Fundamental
- Price
- TOPS $5.98
- MURA $1.55
- Analyst Decision
- TOPS
- MURA Strong Buy
- Analyst Count
- TOPS 0
- MURA 3
- Target Price
- TOPS N/A
- MURA $12.00
- AVG Volume (30 Days)
- TOPS 14.5K
- MURA 205.0K
- Earning Date
- TOPS 08-19-2025
- MURA 08-04-2025
- Dividend Yield
- TOPS N/A
- MURA N/A
- EPS Growth
- TOPS N/A
- MURA N/A
- EPS
- TOPS 1.09
- MURA N/A
- Revenue
- TOPS $86,127,000.00
- MURA N/A
- Revenue This Year
- TOPS $9.90
- MURA N/A
- Revenue Next Year
- TOPS N/A
- MURA N/A
- P/E Ratio
- TOPS $5.26
- MURA N/A
- Revenue Growth
- TOPS 3.83
- MURA N/A
- 52 Week Low
- TOPS $5.00
- MURA $0.95
- 52 Week High
- TOPS $11.47
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- TOPS 48.69
- MURA 15.06
- Support Level
- TOPS $5.65
- MURA $1.53
- Resistance Level
- TOPS $6.28
- MURA $2.40
- Average True Range (ATR)
- TOPS 0.41
- MURA 0.15
- MACD
- TOPS -0.01
- MURA -0.09
- Stochastic Oscillator
- TOPS 48.48
- MURA 2.06
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.